The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer Disease: A Meta-analysis
Open accessAbstract
Importance: It is unclear whether female carriers of the apolipoprotein E (APOE) ε4 allele are at greater risk of developing Alzheimer disease (AD) than men, and the sex-dependent association of mild cognitive impairment (MCI) and APOE has not been established. Objective: To determine how sex and APOE genotype affect the risks for developing MCI and AD. Data Sources: Twenty-seven independent research studies in the Global Alzheimer's Association Interactive Network with data on nearly 58 000 participants. Study Selection: Non-Hispanic white individuals with clinical diagnostic and APOE genotype data. Data Extraction and Synthesis: Homogeneous data sets were pooled in case-control analyses, and logistic regression models were used to compute risks. Main Outcomes and Measures: Age-adjusted odds ratios (ORs) and 95% confidence intervals for developing MCI and AD were calculated for men and women across APOE genotypes. Results: Participants were men and women between ages 55 and 85 years. Across data sets most participants were white, and for many participants, racial/ethnic information was either not collected or not known. Men (OR, 3.09; 95% CI, 2.79-3.42) and women (OR, 3.31; CI, 3.03-3.61) with the APOE ε3/ε4 genotype from ages 55 to 85 years did not show a difference in AD risk; however, women had an increased risk compared with men between the ages of 65 and 75 years (women, OR, 4.37; 95% CI, 3.82-5.00; men, OR, 3.14; 95% CI, 2.68-3.67; P = .002). Men with APOE ε3/ε4 had an increased risk of AD compared with men with APOE ε3/ε3. The APOE ε2/ε3 genotype conferred a protective effect on women (OR, 0.51; 95% CI, 0.43-0.61) decreasing their risk of AD more (P value = .01) than men (OR, 0.71; 95% CI, 0.60-0.85). There was no difference between men with APOE ε3/ε4 (OR, 1.55; 95% CI, 1.36-1.76) and women (OR, 1.60; 95% CI, 1.43-1.81) in their risk of developing MCI between the ages of 55 and 85 years, but women had an increased risk between 55 and 70 years (women, OR, 1.43; 95% CI, 1.19-1.73; men, OR, 1.07; 95% CI, 0.87-1.30; P = .05). There were no significant differences between men and women in their risks for converting from MCI to AD between the ages of 55 and 85 years. Individuals with APOE ε4/ε4 showed increased risks vs individuals with ε3/ε4, but no significant differences between men and women with ε4/ε4 were seen. Conclusions and Relevance: Contrary to long-standing views, men and women with the APOE ε3/ε4 genotype have nearly the same odds of developing AD from age 55 to 85 years, but women have an increased risk at younger ages.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“APOE-e4 was related to higher Alzheimer's risk in women than men between ages 55 to 70”
From 2023 Alzheimer's disease facts and figures (2023) · cites this paper as [288]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Carrying one APOE4 allele increases the risk of AD by 3–4 times, and carrying two alleles increases the risk by 9–15 times.168”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [168]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Women are more vulnerable to effects of APOE4 on memory decline [45] as well as risk for AD dementia [16] and neuropathology [46], and more limited data suggest that APOE2 also confers greater protection against AD risk for women than men [16].”
From Effects of APOE2 and APOE4 on brain microstructure in older adults: modification by age, sex, and cognitive status (2024) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“That is, APOE‐e4 was related to higher Alzheimer's risk in women than men between ages 55 and 70, when APOE is thought to exert its largest effects.”
From 2024 Alzheimer's disease facts and figures (2024) · cites this paper as [314]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A recent meta-analysis found no difference between men and women in the association between APOE-e4 and Alzheimer's dementia overall, although age played an interesting interactive role.”
From 2023 Alzheimer's disease facts and figures (2023) · cites this paper as [288]
The cited source says what the claim attributes to it.
In the citing paper
“APOE is differentially associated with AD risk across populations [16]”
From Effects of APOE2 and APOE4 on brain microstructure in older adults: modification by age, sex, and cognitive status (2024) · cites this paper as [16]
The cited source says what the claim attributes to it.
In the citing paper
“Women are more vulnerable to effects of APOE4 on memory decline [45] as well as risk for AD dementia [16] and neuropathology [46], and more limited data suggest that APOE2 also confers greater protection against AD risk for women than men [16].”
From Effects of APOE2 and APOE4 on brain microstructure in older adults: modification by age, sex, and cognitive status (2024) · cites this paper as [16]
The cited source says what the claim attributes to it.
In the citing paper
“However, a meta‐analysis found no difference between men and women in the association between APOE‐e4 and Alzheimer's dementia overall, although age played an interesting interactive role.”
From 2024 Alzheimer's disease facts and figures (2024) · cites this paper as [314]
The cited source says what the claim attributes to it.
In the citing paper
“Epidemiologic studies show sex differences in clinical risk are largely discernable within the context of APOE ε4,11,42,43 particularly between the ages of 65 to 75 years compared with APOE ε4 clinically normal male carriers.44”
From Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults (2019) · cites this paper as [44]
In the citing paper
“Attempts to quantify the duration of AD should be age-specific, because age imposes the greatest risk for both dementia and mortality, and take into account APOE genotype, sex, and cerebrospinal fluid (CSF) tau levels [4, 6, 10-12].”
From Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype (2019) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459
The projected effect of risk factor reduction on Alzheimer's disease prevalence
Barnes, D. E., & Yaffe, K. S. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70072-2 · Cited by 2,846
Mixed brain pathologies account for most dementia cases in community-dwelling older persons
Schneider, J. A., Arvanitakis, Z., Bang, W., & Bennett, D. A. (2007) · Neurology · doi:10.1212/01.wnl.0000271090.28148.24 · Cited by 1,992
Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database
Bertram, L., McQueen, M. B., Mullin, K., Blacker, D., & Tanzi, R. E. (2007) · Nature Genetics · doi:10.1038/ng1934 · Cited by 1,857
Mild cognitive impairment: a concept in evolution
Petersen, R. C., Caracciolo, B., Brayne, C., Gauthier, S., Jelic, V., & Fratiglioni, L. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12190 · Cited by 1,694
The normal menopause transition
McKinlay, S. M., Brambilla, D. J., & Posner, J. G. (1992) · Maturitas · doi:10.1016/0378-5122(92)90003-m · Cited by 1,112
Sex Differences in Stroke Epidemiology
Appelros, P., Stegmayr, B., & Terént, A. (2009) · Stroke · doi:10.1161/strokeaha.108.540781 · Cited by 1,076
Natural history of mild cognitive impairment in older persons
Bennett, D. A., Wilson, R. S., Schneider, J. A., Evans, D. A., Beckett, L. A., Aggarwal, N. T., Barnes, L. L., Fox, J. H., & Bach, J. (2002) · Neurology · doi:10.1212/wnl.59.2.198 · Cited by 1,037
Clinical epidemiology of Alzheimer’s disease: assessing sex and gender differences
Mielke, M., Vemuri, P., & Rocca, W. (2014) · Clinical Epidemiology · doi:10.2147/clep.s37929 · Cited by 1,021
Ellis, K. A., Bush, A. I., Darby, D., Fazio, D. D., Foster, J. K., Hudson, P. J., Lautenschlager, N. T., Lenzo, N. P., Martins, R. N., Maruff, P. T., et al. (2009) · International Psychogeriatrics · doi:10.1017/s1041610209009405 · Cited by 1,005
Flagged first, then by citations
Cited by
Sorted by citations
2023 Alzheimer's disease facts and figures
(2023) · Alzheimer's & Dementia · doi:10.1002/alz.13016 · Cited by 3,212
2024 Alzheimer's disease facts and figures
(2024) · Alzheimer's & Dementia · doi:10.1002/alz.13809 · Cited by 2,536
2019 Alzheimer’s disease facts and figures.
Alzheimer's Association (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.01.010 · Cited by 2,461
2022 Alzheimer's disease facts and figures
Anonymous (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12638 · Cited by 2,469
2020 Alzheimer's disease facts and figures
(2020) · Alzheimer's & Dementia · doi:10.1002/alz.12068 · Cited by 2,353
2021 Alzheimer's disease facts and figures
Anonymous (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12328 · Cited by 2,339
Sex and gender: modifiers of health, disease, and medicine
Mauvais-Jarvis, F., Bairey Merz, N., Barnes, P. J., Brinton, R. D., Carrero, J.-J., DeMeo, D. L., De Vries, G. J., Epperson, C. N., Govindan, R., Klein, S. L., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31561-0 · Cited by 2,001
2018 Alzheimer's disease facts and figures
Alzheimer's Association (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.001 · Cited by 1,912
Role of neuroinflammation in neurodegeneration development
Zhang, W., Xiao, D., Mao, Q., & Xia, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01486-5 · Cited by 1,668
Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies
Yamazaki, Y., Zhao, N., Caulfield, T. R., Liu, C.-C., & Bu, G. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0228-7 · Cited by 1,425
Sex differences in Alzheimer disease — the gateway to precision medicine
for the Women’s Brain Project and the Alzheimer Precision Medicine Initiative, Ferretti, M. T., Iulita, M. F., Cavedo, E., Chiesa, P. A., Schumacher Dimech, A., Santuccione Chadha, A., Baracchi, F., Girouard, H., Misoch, S., et al. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0032-9 · Cited by 1,009
Lecanemab: Appropriate Use Recommendations
Cummings, J., Apostolova, L., Rabinovici, G. D., Atri, A., Aisen, P., Greenberg, S., Hendrix, S., Selkoe, D., Weiner, M., Petersen, R. C., et al. (2023) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2023.30 · Cited by 961
Understanding the impact of sex and gender in Alzheimer’s disease: A call to action
Nebel, R. A., Aggarwal, N. T., Barnes, L. L., Gallagher, A., Goldstein, J. M., Kantarci, K., Mallampalli, M. P., Mormino, E. C., Scott, L., Yu, W. H., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.04.008 · Cited by 839
A Quarter Century of APOE and Alzheimer’s Disease: Progress to Date and the Path Forward
Belloy, M. E., Napolioni, V., & Greicius, M. D. (2019) · Neuron · doi:10.1016/j.neuron.2019.01.056 · Cited by 570
Vermunt, L., Sikkes, S. A. M., van den Hout, A., Handels, R., Bos, I., van der Flier, W. M., Kern, S., Ousset, P., Maruff, P., Skoog, I., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.04.001 · Cited by 570
2025 Alzheimer's disease facts and figures
(2025) · Alzheimer s & Dementia · doi:10.1002/alz.70235 · Cited by 642
Differences Between Women and Men in Incidence Rates of Dementia and Alzheimer’s Disease
Beam, C. R., Kaneshiro, C., Jang, J. Y., Reynolds, C. A., Pedersen, N. L., & Gatz, M. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-180141 · Cited by 550
Alzheimer’s disease: insights into pathology, molecular mechanisms, and therapy
Zheng, Q., & Wang, X. (2024) · Protein & Cell · doi:10.1093/procel/pwae026 · Cited by 483
Yin, F. (2023) · The FEBS Journal · doi:10.1111/febs.16344 · Cited by 441
Buckley, R. F., Mormino, E. C., Rabin, J. S., Hohman, T. J., Landau, S., Hanseeuw, B. J., Jacobs, H. I. L., Papp, K. V., Amariglio, R. E., Properzi, M. J., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2018.4693 · Cited by 373
The China Alzheimer Report 2022
Ren, R., Qi, J., Lin, S., Liu, X., Yin, P., Wang, Z., Tang, R., Wang, J., Huang, Q., Li, J., et al. (2022) · General Psychiatry · doi:10.1136/gpsych-2022-100751 · Cited by 357
Self-citationAPOE and Alzheimer’s Disease: From Lipid Transport to Physiopathology and Therapeutics
Husain, M. A., Laurent, B., & Plourde, M. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.630502 · Cited by 353
Sex-Specific Association of Apolipoprotein E With Cerebrospinal Fluid Levels of Tau
Hohman, T. J., Dumitrescu, L., Barnes, L. L., Thambisetty, M., Beecham, G., Kunkle, B., Gifford, K. A., Bush, W. S., Chibnik, L. B., Mukherjee, S., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.0821 · Cited by 340
Self-citationAPOE4 disrupts intracellular lipid homeostasis in human iPSC-derived glia
Sienski, G., Narayan, P., Bonner, J. M., Kory, N., Boland, S., Arczewska, A. A., Ralvenius, W. T., Akay, L., Lockshin, E., He, L., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz4564 · Cited by 336
APOE Genotype and Alzheimer Disease Risk Across Age, Sex, and Population Ancestry
Belloy, M. E., Andrews, S. J., Le Guen, Y., Cuccaro, M., Farrer, L. A., Napolioni, V., & Greicius, M. D. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.3599 · Cited by 320
The Wisconsin Registry for Alzheimer's Prevention: A review of findings and current directions
Johnson, S. C., Koscik, R. L., Jonaitis, E. M., Clark, L. R., Mueller, K. D., Berman, S. E., Bendlin, B. B., Engelman, C. D., Okonkwo, O. C., Hogan, K. J., et al. (2017) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.11.007 · Cited by 310
Self-citationAPOE2: protective mechanism and therapeutic implications for Alzheimer’s disease
Li, Z., Shue, F., Zhao, N., Shinohara, M., & Bu, G. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00413-4 · Cited by 306
Apolipoprotein E in lipid metabolism and neurodegenerative disease
Yang, L. G., March, Z. M., Stephenson, R. A., & Narayan, P. S. (2023) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2023.05.002 · Cited by 286
Buckley, R. F., Mormino, E. C., Amariglio, R. E., Properzi, M. J., Rabin, J. S., Lim, Y. Y., Papp, K. V., Jacobs, H. I. L., Burnham, S., Hanseeuw, B. J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.04.010 · Cited by 276
Sexual dimorphism in predisposition to Alzheimer's disease
Fisher, D. W., Bennett, D. A., & Dong, H. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.04.004 · Cited by 270
D’Amato, A., Di Cesare Mannelli, L., Lucarini, E., Man, A. L., Le Gall, G., Branca, J. J. V., Ghelardini, C., Amedei, A., Bertelli, E., Regoli, M., et al. (2020) · Microbiome · doi:10.1186/s40168-020-00914-w · Cited by 269
Alzheimer’s pathogenic mechanisms and underlying sex difference
Zhu, D., Montagne, A., & Zhao, Z. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03830-w · Cited by 275
APOE and TREM2 regulate amyloid-responsive microglia in Alzheimer’s disease
Nguyen, A. T., Wang, K., Hu, G., Wang, X., Miao, Z., Azevedo, J. A., Suh, E., Van Deerlin, V. M., Choi, D., Roeder, K., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02200-3 · Cited by 241
Tran, T. T. T., Corsini, S., Kellingray, L., Hegarty, C., Le Gall, G., Narbad, A., Müller, M., Tejera, N., O'Toole, P. W., Minihane, A.-M., et al. (2019) · The FASEB Journal · doi:10.1096/fj.201900071r · Cited by 233
The Role of Sex and Sex Hormones in Neurodegenerative Diseases
Vegeto, E., Villa, A. M., Torre, S. D., Crippa, V., Rusmini, P., Cristofani, R., Galbiati, M., Maggi, A. C., & Poletti, A. (2019) · Endocrine Reviews · doi:10.1210/endrev/bnz005 · Cited by 240
Alzheimer’s Risk Factors Age, APOE Genotype, and Sex Drive Distinct Molecular Pathways
Zhao, N., Ren, Y., Yamazaki, Y., Qiao, W., Li, F., Felton, L. M., Mahmoudiandehkordi, S., Kueider-Paisley, A., Sonoustoun, B., Arnold, M., et al. (2020) · Neuron · doi:10.1016/j.neuron.2020.02.034 · Cited by 225
Sex and gender differences in cognitive resilience to aging and Alzheimer's disease
Arenaza‐Urquijo, E. M., Boyle, R., Casaletto, K., Anstey, K. J., Vila‐Castelar, C., Colverson, A., Palpatzis, E., Eissman, J. M., Kheng Siang Ng, T., Raghavan, S., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13844 · Cited by 223
Updates in Alzheimer's disease: from basic research to diagnosis and therapies
Liu, E., Zhang, Y., & Wang, J. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00432-x · Cited by 241
Self-citationSex differences in Alzheimer's disease
Laws, K. R., Irvine, K., & Gale, T. M. (2018) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000401 · Cited by 216
Sex and APOE ε4 genotype modify the Alzheimer’s disease serum metabolome
Arnold, M., Nho, K., Kueider-Paisley, A., Massaro, T., Huynh, K., Brauner, B., MahmoudianDehkordi, S., Louie, G., Moseley, M. A., Thompson, J. W., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14959-w · Cited by 202
Causes and Patterns of Dementia: An Update in the Era of Redefining Alzheimer's Disease
James, B. D., & Bennett, D. A. (2019) · Annual Review of Public Health · doi:10.1146/annurev-publhealth-040218-043758 · Cited by 213
Emrani, S., Arain, H. A., DeMarshall, C. A., & Nuriel, T. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00712-4 · Cited by 207
Rahman, A., Jackson, H. C., Hristov, H., Isaacson, R., Saif, N., Shetty, T., Etingin, O. R., Henchcliffe, C., Brinton, R. D., & Mosconi, L. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00315 · Cited by 204
Intranasal Insulin for Alzheimer’s Disease
Hallschmid, M. (2021) · CNS Drugs · doi:10.1007/s40263-020-00781-x · Cited by 188
Toward personalized cognitive diagnostics of at-genetic-risk Alzheimer’s disease
Coughlan, G., Coutrot, A., Khondoker, M. R., Minihane, A. M., Spiers, H. J., & Hornberger, M. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1901600116 · Cited by 191
Health comorbidities and cognitive abilities across the lifespan in Down syndrome
Startin, C. M., D’Souza, H., Ball, G., Hamburg, S., Hithersay, R., Hughes, K. M. O., Massand, E., Karmiloff‐Smith, A., Thomas, M. S. C., & Strydom, A. (2020) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-019-9306-9 · Cited by 179
Sex Differences in Alzheimer’s Disease
Aggarwal, N. T., & Mielke, M. M. (2023) · Neurologic Clinics · doi:10.1016/j.ncl.2023.01.001 · Cited by 184
Gene-environment interactions in Alzheimer's disease: A potential path to precision medicine
Eid, A., Mhatre, I., & Richardson, J. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.03.005 · Cited by 164
Sex Differences in Alzheimer’s Disease: Insights From the Multiomics Landscape
Guo, L., Zhong, M. B., Zhang, L., Zhang, B., & Cai, D. (2022) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.02.968 · Cited by 164
Saleh, R. N. M., Hornberger, M., Ritchie, C. W., & Minihane, A. M. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01121-5 · Cited by 162
Metabolic Syndrome as a Risk Factor for Alzheimer’s Disease: A Focus on Insulin Resistance
Ezkurdia, A., Ramírez, M. J., & Solas, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054354 · Cited by 160
Gurvich, C., Hoy, K., Thomas, N., & Kulkarni, J. (2018) · Brain Sciences · doi:10.3390/brainsci8090163 · Cited by 150
Ferretti, M. T., Martínková, J., Biskup, E. M., Benke, T., Gialdini, G., Nedelská, Z., Rauen, K., Mantua, V., Religa, D., Hort, J., et al. (2020) · European Journal of Neurology · doi:10.1111/ene.14174 · Cited by 152
APOE alleles and diet in brain aging and Alzheimer's disease
Yassine, H. N., & Finch, C. E. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00150 · Cited by 145
Gong, J., Harris, K., Lipnicki, D. M., Castro‐Costa, E., Lima‐Costa, M. F., Diniz, B. S., Xiao, S., Lipton, R. B., Katz, M. J., Wang, C., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12962 · Cited by 141
Interpretation and Potential Biases of Mendelian Randomization Estimates With Time-Varying Exposures
Labrecque, J. A., & Swanson, S. A. (2019) · American Journal of Epidemiology · doi:10.1093/aje/kwy204 · Cited by 139
Drug development for alzheimer’s disease: Microglia induced neuroinflammation as a target
Dong, Y., Li, X., Cheng, J., & Hou, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030558 · Cited by 136
Anstey, K. J., Peters, R. K., Mortby, M. E., Kiely, K. M., Eramudugolla, R., Cherbuin, N., Huque, M. H., & Dixon, R. A. (2021) · Scientific Reports · doi:10.1038/s41598-021-86397-7 · Cited by 142
Protective genes and pathways in Alzheimer’s disease: moving towards precision interventions
Seto, M., Weiner, R. L., Dumitrescu, L., & Hohman, T. J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00452-5 · Cited by 135
An exhausted-like microglial population accumulates in aged and APOE4 genotype Alzheimer’s brains
Millet, A., Ledo, J. H., & Tavazoie, S. F. (2024) · Immunity · doi:10.1016/j.immuni.2023.12.001 · Cited by 132
Temporal Dynamics of β-Amyloid Accumulation in Aging and Alzheimer Disease
Jagust, W. J., Landau, S. M., & Jack, C. R. (2021) · Neurology · doi:10.1212/wnl.0000000000011524 · Cited by 125
Rabinovici, G. D. (2019) · Continuum · doi:10.1212/con.0000000000000700 · Cited by 170
Predicting future rates of tau accumulation on PET
Jack, C. R., Wiste, H. J., Weigand, S. D., Therneau, T. M., Lowe, V. J., Knopman, D. S., Botha, H., Graff-Radford, J., Jones, D. T., Ferman, T. J., et al. (2020) · Brain · doi:10.1093/brain/awaa248 · Cited by 117
Heart–brain interactions in cardiac and brain diseases: why sex matters
Rossi, A., Mikaïl, N., Bengs, S., Haider, A., Treyer, V., Buechel, R. R., Wegener, S., Rauen, K., Tawakol, A. A., Merz, C. N. B., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac061 · Cited by 124
Exercise and the Aging Brain: Considerations for Sex Differences
Barha, C. K., & Liu-Ambrose, T. Y. L. (2018) · Brain Plasticity · doi:10.3233/bpl-180067 · Cited by 126
Belloy, M. E., Napolioni, V., Han, S. S., Le Guen, Y., Greicius, M. D., & Initiative, F. T. A. D. N. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.0414 · Cited by 110
Sex-specific genetic predictors of Alzheimer’s disease biomarkers
(ADNI), A. D. N. I., Deming, Y., The Alzheimer Disease Genetics Consortium (ADGC), Dumitrescu, L., Barnes, L. L., Thambisetty, M., Kunkle, B., Gifford, K. A., Bush, W. S., Chibnik, L. B., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1881-4 · Cited by 110
Self-citationThe Alzheimer's Disease Exposome
Finch, C. E., & Kulminski, A. M. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.06.3914 · Cited by 114
Cavedo, E., Chiesa, P. A., Houot, M., Ferretti, M. T., Grothe, M. J., Teipel, S. J., Lista, S., Habert, M., Potier, M., Dubois, B., et al. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.05.014 · Cited by 111
Duong, M. T., Nasrallah, I. M., Wolk, D. A., Chang, C. C. Y., & Chang, T. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.647990 · Cited by 110
Sex-specific norms for verbal memory tests may improve diagnostic accuracy of amnestic MCI
Sundermann, E. E., Maki, P. M., Biegon, A. R., Lipton, R. B., Mielke, M. M., Machulda, M. M., Bondi, M. W., & Initiative, A. D. N. (2019) · Neurology · doi:10.1212/wnl.0000000000008467 · Cited by 105
Sex differences in Alzheimer’s-related Tau biomarkers and a mediating effect of testosterone
Sundermann, E. E., Panizzon, M. S., Chen, X., Andrews, M., Galasko, D. R., Banks, S. J., & Initiative, A. D. N. (2020) · Biology of Sex Differences · doi:10.1186/s13293-020-00310-x · Cited by 110
Sex differences in the genetic architecture of cognitive resilience to Alzheimer’s disease
Eissman, J. M., Dumitrescu, L. C., Mahoney, E. R., Smith, A. N., Mukherjee, S., Lee, M. L., Scollard, P., Choi, S. E., Bush, W. S., Engelman, C. D., et al. (2022) · Brain · doi:10.1093/brain/awac177 · Cited by 103
Self-citationMenopause Status Moderates Sex Differences in Tau Burden: A Framingham PET Study
Buckley, R. F., O’Donnell, A., McGrath, E. R., Jacobs, H. I. L., Lois, C., Satizábal, C. L., Ghosh, S., Rubinstein, Z. B., Murabito, J. M., Sperling, R. A., et al. (2022) · Annals of Neurology · doi:10.1002/ana.26382 · Cited by 101
Sex differences in Alzheimer’s disease: Understanding the molecular impact
Toro, C. A., Zhang, L., Cao, J., & Cai, D. (2019) · Brain Research · doi:10.1016/j.brainres.2019.05.031 · Cited by 105
Sex differences in the genetic predictors of Alzheimer’s pathology
Dumitrescu, L., Barnes, L. L., Thambisetty, M., Beecham, G., Kunkle, B., Bush, W. S., Gifford, K. A., Chibnik, L. B., Mukherjee, S., De Jager, P. L., et al. (2019) · Brain · doi:10.1093/brain/awz206 · Cited by 93
Self-citationMattsson, N., Groot, C., Jansen, W. J., Landau, S. M., Villemagne, V. L., Engelborghs, S., Mintun, M. M., Lleo, A., Molinuevo, J. L., Jagust, W. J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.009 · Cited by 88
Self-citationDubal, D. B. (2020) · Handbook of clinical neurology · doi:10.1016/b978-0-444-64123-6.00018-7 · Cited by 92
APOE ɛ4 dose associates with increased brain iron and β-amyloid via blood–brain barrier dysfunction
Uchida, Y., Kan, H., Sakurai, K., Horimoto, Y., Hayashi, E., Iida, A., Okamura, N., Oishi, K., & Matsukawa, N. (2022) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-328519 · Cited by 84
Gamache, J., Yun, Y., & Chiba-Falek, O. (2020) · Disease Models & Mechanisms · doi:10.1242/dmm.045211 · Cited by 84
Sex and gender considerations in Alzheimer’s disease: The Women’s Brain Project contribution
Castro‐Aldrete, L., Moser, M. V., Putignano, G., Ferretti, M. T., Dimech, A. S., & Chadha, A. S. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1105620 · Cited by 87
Sex differences in CSF biomarkers vary by Alzheimer disease stage and APOE ε4 genotype
Mofrad, R. B., Tijms, B. M., Scheltens, P., Barkhof, F., van der Flier, W. M., Sikkes, S. A. M., & Teunissen, C. E. (2020) · Neurology · doi:10.1212/wnl.0000000000010629 · Cited by 84
Effects of intermittent fasting on cognitive health and Alzheimer’s disease
Elias, A., Padinjakara, N., & Lautenschlager, N. T. (2023) · Nutrition Reviews · doi:10.1093/nutrit/nuad021 · Cited by 85
Vitamin B12 Deficiency and the Role of Gender: A Cross-Sectional Study of a Large Cohort
Margalit, I., Cohen, E., Goldberg, E., & Krause, I. (2018) · Annals of Nutrition and Metabolism · doi:10.1159/000488326 · Cited by 78
Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer’s disease
Milà‐Alomà, M., Suárez‐Calvet, M., & Molinuevo, J. L. (2019) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286419888819 · Cited by 81
Hampel, H., Shaw, L. M., Aisen, P., Chen, C., Lleó, A., Iwatsubo, T., Iwata, A., Yamada, M., Ikeuchi, T., Jia, J., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12372 · Cited by 77
Zhu, Z., Ma, X., Wu, J., Xiao, Z., Wu, W., Ding, S., Zheng, L., Liang, X., Luo, J., Ding, D., et al. (2022) · Nutrients · doi:10.3390/nu14193959 · Cited by 80
Sex differences in longitudinal tau-PET in preclinical Alzheimer disease: a meta-analysis
Coughlan, G. T., Klinger, H. M., Boyle, R., Betthauser, T. J., Binette, A. P., Christenson, L., Chadwick, T., Hansson, O., Harrison, T. M., Healy, B., et al. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2025.0013 · Cited by 69
Self-citationRemembering your A, B, C's: Alzheimer's disease and ABCA1
Lewandowski, C. T., Laham, M. S., & Thatcher, G. R. J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.01.011 · Cited by 76
Nicoletti, A. S. Q., Baschi, R., Cicero, C. E., Iacono, S., Re, V. L., Luca, A., Schirò, G., & Monastero, R. (2023) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2023.111821 · Cited by 79
Primary Tau Pathology, Not Copathology, Correlates With Clinical Symptoms in PSP and CBD
Robinson, J. L., Yan, N., Caswell, C., Xie, S. X., Suh, E. R., Deerlin, V. M. V., Gibbons, G. S., Irwin, D. J., Grossman, M., Lee, E. B., et al. (2019) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlz141 · Cited by 77
Qiao, Y., Chi, Y., Zhang, Q., & Ma, Y. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1169499 · Cited by 78
Neuroimmune contributions to Alzheimer’s disease: a focus on human data
Haage, V., & De Jager, P. L. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01637-0 · Cited by 74
Blanco, K., Salcidua, S., Orellana, P., Sauma-Pérez, T., León, T., Steinmetz, L. C. L., Ibañez, A., Duran-Aniotz, C., & de la Cruz, R. (2023) · Alzheimer's Research & Therapy · doi:10.1186/s13195-023-01304-8 · Cited by 73
APOE4 confers transcriptomic and functional alterations to primary mouse microglia
Machlovi, S. I., Neuner, S. M., Hemmer, B. M., Khan, R., Liu, Y., Huang, M., Zhu, J. D., Castellano, J. M., Cai, D., Marcora, E., et al. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105615 · Cited by 73
MicroRNAs as diagnostic and therapeutic tools for Alzheimer’s disease: advances and limitations
Peplow, P., & Martinez, B. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.244784 · Cited by 74
Tomaszewski, N., He, X., Solomon, V. A., Lee, M. B., Mack, W. J., Quinn, J. F., Braskie, M. N., & Yassine, H. N. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191017 · Cited by 77
Boxer, A. L., Gold, M., Feldman, H., Boeve, B. F., Dickinson, S. L.-J., Fillit, H., Ho, C., Paul, R., Pearlman, R., Sutherland, M., et al. (2020) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.06.4956 · Cited by 71
Ramanan, V. K., Castillo, A. M., Knopman, D. S., Graff‐Radford, J., Lowe, V. J., Petersen, R. C., Jack, C. R., Mielke, M. M., & Vemuri, P. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.13909 · Cited by 74
Insights into Computational Drug Repurposing for Neurodegenerative Disease
Paranjpe, M. D., Taubes, A. L., & Sirota, M. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.06.003 · Cited by 72
Metadata
- Authors
- Neu, S. C., Pa, J., Kukull, W., Beekly, D., Kuzma, A., Gangadharan, P., Wang, L.-S., Romero, K., Arneric, S. P., Redolfi, A., Orlandi, D., Frisoni, G. B., Au, R., Devine, S., Auerbach, S., Espinosa, A., Boada, M., Ruiz, A., Johnson, S. C., Koscik, R., Wang, J.-J., Hsu, W.-C., Chen, Y.-L., & Toga, A. W.
- Affiliations
- University of Southern California (US)
- University of Washington (US)
- University of Pennsylvania (US)
- Critical Path Institute (US)
- Coalition Against Major Disease, Critical Path Institute, Tucson, Arizona
- Centro San Giovanni di Dio Fatebenefratelli (IT)
- University of Geneva (CH)
- Boston University (US)
- Fundació ACE (ES)
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain
- University of Wisconsin–Madison (US)
- Chang Gung University (TW)
- Chang Gung Memorial Hospital (TW)
- Corresponding author
- Toga, Arthur W.
- ORCID
- Venue
- JAMA Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2017-10-01
- Volume
- 74
- Issue
- 10
- Pages
- 1178
- ISSN
- 2168-6149 (ISSN-L)
- PMC
- PMC5759346
- OpenAlex
- W2745657465
- Cited by
- 674
- References
- 74
- Citations by year
- 2026: 74 · 2025: 81 · 2024: 74 · 2023: 93 · 2022: 78 · 2021: 96 · 2020: 69 · 2019: 67 · 2018: 37 · 2017: 3
- FWCI
- 39.51
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- JAMA Neurology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR000130, 5u01ag024904-10, n01hc25195-41-0-1, UL1TR001855)
- U.S. Food and Drug Administration (U18FD005320)
- National Institute on Aging (U01-AG-024904, P30AG010129, P30AG010133, P30AG028383, P30AG012300, P50AG005133, U01AG016976, P50AG005131, P50AG005138, P50AG016570, P30AG010124, P50AG016573, RF1AG027161, P50AG047366, P30AG008017, P30AG010161, R01AG033040, P30AG008051, P50AG008702, R01AG016495, P50AG033514, P30AG035982, P50AG005681, P50AG005142, P50AG047270, P30AG019610, P50AG005146, P01AG003991, RF1AG054617, P30AG013846, P50AG005136, P50AG005134, P30AG013854, P50AG025688, P50AG047266, R01AG008122, R01AG027161, U24AG041689, U19AG024904, P01AG026276, P50AG023501, P50AG016574)
- National Heart, Lung, and Blood Institute (N01-HC-025195)
- National Institute of Neurological Disorders and Stroke (R01NS017950)
- National Institute of Biomedical Imaging and Bioengineering (U54EB020406, P41EB015922)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- Alzheimer's disease, apolipoprotein E, APOE ε4, APOE ε2, sex differences, mild cognitive impairment, genetic risk factors
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Apolipoproteins E, Female, Humans, Male, Middle Aged, Risk Factors, Sex Characteristics, Logistic Models, Case-Control Studies, Databases, Factual
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
